Firms To Watch: Life sciences and healthcare: PRC firms

Commerce & Finance Law Offices is noted for its strong track record in handling large IPOs, M&A and cross-border financings on behalf of medical device companies, pharmaceutical groups, and biotech and medtech start-ups.
With offices in Shanghai, Shenzhen and Wuhan, the life sciences and healthcare team at East & Concord Partners handles M&A, corporate compliance, drug licensing transactions, IP matters and anti-trust issues.
Llinks Law Offices is noted for is particularly noted for its wealth of experience acting for large, medium and start-up companies on a wide range of matters, spanning M&A, investment rounds, IP, licensing deals and regulatory compliance.

Life sciences and healthcare: PRC firms in China

Fangda Partners

Fangda Partners houses ‘a highly competent team of life sciences and healthcare lawyers’, who are equipped to handle the whole life cycle of life sciences and health products’. Highly praised for its ability to combine expertise from many practice areas within the firm’, the practice assists a stellar list of clients with financings, rights issuances, regulatory compliance, licensing applications, IP disputes, and antitrust matters. With ‘many years of experience in the biomedical industry’, Shanghai-based Josh Shin regularly advises on distribution and collaboration agreements. In Beijing, Kate Yin focuses on regulatory compliance and enforcement actions while Fang Qi handles IP transactions and antitrust litigation. M&A, foreign investment and PE matters are the area of expertise of Shanghai-based Diana Li. Splitting his time between Beijing and Hong Kong, Michael Han is recommended for joint ventures and antitrust investigations. Sherry Yao departed in April 2022.

Practice head(s):

Josh Shin; Kate Yin; Michael Han; Fang Qi

Other key lawyers:

Yiren Hu; Gil Zhang

Testimonials

‘They work as a very strong team with exceptional depth in expertise and breadth of work scope. The team has an excellent business sense besides their outstanding legal skills.’

‘Josh Shin has very good business sense and is always on top of all matters. Yiren Hu is very detail oriented and skilled in cross-border transactions.’

‘Fangda has a highly competent team of life sciences and healthcare lawyers. The practice covers legal services related to the whole life cycle of life sciences and health products. They provide our company with multi-faceted and multi-dimensional legal advice such as BD, clinical, listing access, advertising, antitrust, data and personal information protection.’

‘Diana Li has a thorough understanding of and many years of experience in the life sciences and healthcare industry, with a with a deep understanding of new technologies and products.’

‘Fangda’s life sciences and healthcare team is able to combine expertise from many practice areas within the firm  to provide comprehensive high-quality legal services.’

‘Josh Shin is a distinguished partner in Fangda’s life sciences and healthcare team. He is able to quickly understand the company’s business model and provide timely high-quality advice.’

‘Josh Shin has many years of experience in the biomedical industry, being familiar with professional investors and start-up companies operating in the industry.’

‘Josh Shi and Gil Zhang have good understanding of the client business model and the complex regulatory framework which impacts the client’s business.’ 

Key clients

Novartis

Bayer Healthcare

AstraZeneca

Roche China

Gilead Sciences

Abbott China

WuXi AppTech

Watson Pharmaceuticals

Mindray Medical

APBI Holdings

Danaher Corporate

Fresenius Kabi

BioGene

BeiGene

Yunfeng Fund II

TPG Growth

Yunfeng Capital

Sino Medcare

Roper Technology

Assembly BioScience

Edding Pharm

Everbright Healthcare Fund

C-Stone Pharmaceutical

Hanhui Pharma

Shanghai Kehua Bioengineering

Astellas

Brooks Automation

EdiGene Beijing Biotechnology

LifeTech Scientific Corporation

Wuxi JW Therapeutics

CBC Group

PAG

Primavera Capital

CDBI Capital

CICC Healthcare Fund

CVC Capital

Hillhouse Capital

Highlight Capital

Haeir Healthcare

Johnson & Johnson

Straumann

Anheart Therapeutics

Smith & Nephew

MitrAssist

Visen Pharmaceuticals

Laekna Therapeutics

Medela

Smith & Nephew

Vyaire Medical

MSD

Vazyme Biotechnology

Zai Lab

CMS (China Medical System)

CDH Fund

Novotech

MicroPort Group

Cenova Capital

Bristol-Myers Squibb

Medi-Link

I-Mab BioPharma

Brii BioScience

Overland Pharmaceuticals

Oncusp Therapeutics

Galixir Technology

Virogin Biotech

Thermo Fisher

Ortho Diagnostics

Eli Lilly

Takeda

Kintor Pharmaceutical

MediTrust Health

AZ-CICC Healthcare Fund

magAssist Technology

Perkin Elmer

Beijing Naton Technology

Work highlights

  • Advised BeiGene on its $3.5bn (before over-allotment option is fully exercised) initial public offering and listing on the STAR Market Shanghai, after acting  for BeiGene as the company PRC counsel on its IPOs on NASDAQ and HKEX.
  • Assisted CStone Pharmaceuticals in granting exclusive rights to Hengrui Pharmaceuticals for research, development, registration, manufacturing, and commercialisation of anti-CTLA-4 mAb CS1002 in the Greater China region.
  • Acted for MediTrust Health on its Series-C financing co-lead by Boyu Capital and Janchor Partners, involving an aggregate financing amount of over ¥2bn.

Global Law Office

The dedicated life science and healthcare team at Global Law Office is rated for its ‘strong and longstanding reputation in the market’ and its full-service offering, which includes M&A, investment transactions, licensing matters, IP, regulatory compliance and litigation. In addition to acting for high-profile pharmaceutical companies such as Johnson & Johnson and AstraZeneca, the practice is often sought after by industry associations and government bodies to assist with policy and regulatory matters. The team is jointly led by ‘distinguished partner’ Alan Zhou, who has extensive experience in advising on private equity and venture capital transactions, and M&A and foreign investment specialist Michael Yu, from Shanghai and Beijing, respectively. Jerry Liumatters focuses on corporate and cross-border M&A matters while Charlene Huang is a key contact for licence deals and outbound and inbound investment. Coco Fan and Jacky Li are recommended for regulatory compliance and antitrust investigations.

Practice head(s):

Alan Zhou; Michael Yu

Other key lawyers:

Jerry Liu; Coco Fan; Charlene Huang; Jack Li

Testimonials

‘Alan Zhou and Coco Fan are very knowledgeable about the pharmaceutical industry, professional and efficient.’

‘Global’s life science and healthcare team has a strong and longstanding reputation in the market. The firm’s in-depth insight into the industry and close connection with legislators are impressive.’

‘Alan Zhou has many years of experience in the industry and his extensive network in the pharmaceutical industry provides a rare opportunity for pharmaceutical companies to participate deeply in relevant legislative discussions.’

‘Very knowledgeable about the pharmaceutical industry, professional and efficient.’

‘Global Law Office is intimately familiar with the life sciences and healthcare sector, and its advice to clients is very pragmatic and innovative. Its lawyers have been in the field for many years and have a deep understanding of the legal, compliance, data protection and IP matters related to the healthcare industry.’

‘Alan Zhou is a distinguished partner with extensive experience in life sciences and healthcare legal and compliance matters. He is good at communicating with clients, understanding client needs, and proposing pragmatic and business-orientated solutions.’

‘Alan Zhou has extensive knowledge of the industry and provides good advice in line with market practices.’

Key clients

Amgen

BMS

Roche

Johnson & Johnson

GSK

Astra Zeneca

BI

Abbott

Shanghai Pharma

Hengrui

Cansino Bio

ZaiLab

CARsgen

I-MAB

C-Stone

Work highlights

  • Acted for Primavera Capital on the $2.2bn acquisition of Mead Johnson from Reckitt Benckiser Group’s Greater China Business.
  • Assisted Jemincare in co-operating with Orion on a new non-opioid analgesic drug, a project valued at $489m.
  • Represented AstraZeneca in its patent infringement litigation appeal proceedings before the Supreme People’s Court against generic manufacturer Jiangsu Aosaikang Pharmaceutical Co., Ltd.

King & Wood Mallesons

With ‘extensive knowledge of investment, licence registration, compliance, and antitrust matters’, the healthcare & pharmaceuticals team at King & Wood Mallesons is on top of key developments and trends in the industry, offering tailored and creative solutions’. Acting for a wide range of clients, including health insurance groups, private equity houses, investors, biotech companies and hospitals, the practice enjoys the ability to leverage the firm’s international network, which makes it well placed to handle cross-border matters. Leading the team from Beijing is Jianwen Huang, who specialises in inbound and outbound investment and M&A mandates. Tina Tai and Wenping Chen are recommended for IP matters, enforcement actions and investigations while Yuanyuan Zhu is a key name for compliance matters and investigations. In Shanghai, Mark Zhang and  Fan Yang handle cross-border investment, M&A and PE matters. Also noted are Shenzhen-based Ting Liu and senior associate Lingbi Li in Shanghai.

Practice head(s):

Jianwen Huang

Other key lawyers:

Tina Tai; Wenping Chen; Mark Zhang; Ting Liu, Fan Wang; Yuanyuan Zhu; Lingbi Li

Testimonials

‘The firm  provides a full range of services and has extensive knowledge of investment, licence registration, compliance, and antitrust matters.’

‘Mark Zhang is an excellent and very professional lawyer, who gives appropriate advice that matches the needs of the client’s business.’

‘King & Wood Mallesons is one of the few law firms in China with a dedicated healthcare team, with deep legal expertise and extensive transactional experience. The team also includes senior lawyers with biomedical background.’

‘They provide clients with a full range of legal services in the field of life sciences and healthcare. They are on top of key developments and trends in the industry, offering clients tailored and creative solutions.’

‘With capabilities in key jurisdictions, including Chinese mainland, Hong Kong, Australia, the United Kingdom, the United States and Europe, King & Wood Mallesons has the ability to assist clients with cross-border transactions and in expanding their businesses overseas.’ 

‘Mark Zhang is able to provide clients with a wide range of comprehensive “one-stop” services, covering pharmaceuticals, medical devices, biotechnology, clinical trials, genetics, healthcare products, hospitals and other medical service providers.’

‘Mark Zhang’s team has a clear understanding of the legal issues involved in transactions, providing clients with clear suggestions and a full picture of the risks involved from the outset.’ 

‘Yang Fan is recommended for the quality of the service provided and his responsiveness.’

Key clients

HUTCHMED (China) Limited

CANbridge Pharmaceuticals Inc

Reckitt Global and Reckitt Benckiser (China) Investment Co., Ltd

Beijing Leto Laboratories Biotechnology Co., Ltd

RemeGen Co., Ltd

Harbin Pharmaceutical Group

Work highlights

  • Advised RemeGen Co., Ltd on its initial public offering of A-shares on the STAR market of the Shanghai Stock Exchange.
  • Acted for Beijing Leto Laboratories Biotechnology Co., Ltd on a joint development agreement with Hanson Pharmaceutical Group Company Limited.
  • Represented Novartis AG in proceedings to maintain the validity of Entresto® compound patent.

Zhong Lun Law Firm

With a deep bench of ‘experts from various fields, including drugs and medical device regulations, data protection and privacy, anti-bribery, antitrust and policy matters’, Zhong Lun Law Firm is equipped to assist clients with the whole chain of the life sciences and healthcare industry, from M&A and IPOs to IP matters and dispute resolution. The practice handles a heavy workload for large multinational pharmaceutical companies, medical groups and private equity firms. With ‘a strong background in biochemistry and pharmacy’, Helen Cheng ‘provides comprehensive legal advice, which covers joint ventures, cross-border transactions, compliance risk assessments, IP due diligence and disputes’. Yongbin Ge is a key contact for capital market matters and PE investment while Changyu Fu is especially sought after to assist clients with criminal litigation, arbitration proceedings and administrative disputes. Other key practitioners include Dongmei Wang, Jim Qiu, associates Qi Lan and IP expert Shuman Zhang.

Practice head(s):

Helen Cheng; Changyu Fu; Dongmei Wang; Yongbin Ge; Jim Qiu

Other key lawyers:

Yuru Zuo; Qi Lan; Shuman Zhang

Testimonials

‘Yuru Zuo offers comprehensive and timely advice that is suitable for the business needs of the client. In the face of unexpected changes, Zuo is professional, skilled and flexible.’

‘The team has a longstanding presence in the medical and healthcare sector, with extensive expertise in cross-border projects and the business operations of pharmaceutical companies.’

‘Helen Cheng has a strong background in biochemistry and pharmacy. He provides comprehensive legal advice, which covers joint ventures, cross-border transactions, compliance risk assessments, IP due diligence and disputes.’

‘Zhong Lun provides strong legal support in the research and development field, and the billing can be adjusted according to the needs of the client.’

‘The team is experienced, the lawyers are responsible and fees are reasonable. Very satisfied.’

‘The team includes legal experts from various fields and business areas, including drugs and medical device regulations, date protection and privacy, anti-bribery, antitrust, and policy matters, efficiently providing excellent results to clients.’ 

‘The team is responsive and provides advice in a timely manner.’

‘Jim Qiu understands our needs and always does his best to explore the best solutions. With extensive experience and insight into the life sciences industry, He always offers innovative and priceless advice. His team is unique and exceptional.’

Key clients

6 Dimensions

Abbott Laboratories

Alebund

Align Technology

Astellas Pharmaceutical(China)Co., Ltd

Baring Private Equity Asia

Beaufour-IPSEN (Tianjin) Pharmaceutical Co., Ltd

BeiGene Shanghai Biotechnology Co., Ltd

Beijing Jingdong Health Co., Ltd

CarsGen

CBC Group

China National Medicines Corporation Ltd

CPIC Capital

Cutia

Eli Lilly and Company

Endeavour Consumer Health Limited

Esco LifeSciences

Exegenesis Bio, Inc.

Fosun Kite Biotechnology Co., Ltd

Frontiers Media

GlaxoSmithKline (China) Investment Co., Ltd

GlaxoSmithKline (China) R&D Co., Ltd

Global Health Drug Discovery Institute

GraCell

Hong Kong Asia Medical Group

HOYA Lens Thailand Ltd

I-Mab

LaNova

Lilly Asia Ventures

Mundipharma (China) Pharmaceutical Co, LTD

Nanjing Leads Biolabs Co., Ltd

Nestle (China) Ltd

Ocumension

PepsiCo Asia R&D Center Ltd

Peter’s Technology

Pfizer Investment Co., Ltd

Sequoia

Shanghai ISO Medical Products Co. Ltd

Shanghai Pharmaceuticals Holding Co., Ltd

Shanghai Roche Pharmaceuticals Ltd

Shanghai SPH Ruier Drugs Co., Ltd

Shanghai Topcare Medical Services Co., Ltd

SinoUnion Healthcare

Stryker (Beijing) Healthcare Products Co., Ltd

Sysmex

The Management Office of All Shanghai Medical Associations

Vision Care, Hoya Group

Yantai Dongcheng Pharmaceutical Group Co., Ltd

Work highlights

  • Assisted Hong Kong Asia Medical Group with its $400m series-D financing.
  • Advised LianBio’s on its IPO on the Nasdaq Stock Market.
  • Acted for Shanghai Topcare on the acquisition of Fullerton Healthcare Corporation Limited.

Han Kun Law Offices

Han Kun Law Offices is highly rated for its ability to ‘assign a team with members from various departments to help with complex matters’. Acting for a varied client roster of pharmaceutical and healthcare companies, investment funds, and private equity and venture capital firms, the practice is recognised for its strong expertise in handling joint ventures, M&A, financial transactions and licensing deals. As part of its broad offering, the group also handles IP matters, regulatory compliance, antitrust issues and litigation. From Shanghai, ‘knowledgeable, patient and accessible’ Yinshi Cao, who focuses on private equity, venture capital and M&A, heads up the group while Min Zhu is recommended for foreign direct investment and corporate restructuring matters. In Beijing, Charles Li is a key contact for equity and debt financings and IP matters, and Aaron Zhou is noted for his expertise in cross-border M&A and licensing deals.

Practice head(s):

Yinshi Cao

Other key lawyers:

Charles Li; Aaron Zhou; Min Zhu; Cheng Chen; Lijuan Wang

Testimonials

‘Professional and in-depth knowledge of the biotech industry. Fair price with engagement of counsels at all level.’

‘Min Zhu, Cheng Chen and Lijuan Wang are recommended.’

‘The team is extremely experienced in cross-border licensing deals. They are very patient to explain all the terms and potential consequences. They are highly efficient at summarising the arguments, making the entire contractual process extremely smooth. They are very collaborative and work very hard over weekends and countless nights. The final bill is very friendly.’

‘The lawyer in charge of the team is very knowledgeable, patient and accessible. Yinshi Cao can explain very complicated situations in an easy way. He thinks about all the potential risks to ensure the licensing deal goes smoothly. He knows how to persuade the other side to agree with his client.’

‘Great quality and thorough legal advice. Great negotiation skills that bring great value to the client.’ 

‘Min Zhu is really impressive.’

‘The team at Han Kun Law Offices is one of the best teams that we have worked with. The team is very accountable and experienced and always provides prompt and excellent support in complex transactions. The unique culture and structure of Han Kun Law Offices ensure it can assign a team with members from various departments to help us deal with complex matters. The team has superior commercial sense in providing solutions and constantly applies accurate commercial judgement to solve transaction obstacles. Lawyers are reachable at any time, including over the weekends, during holidays and in evenings.’

‘Aaron Zhou is very knowledgeable on healthcare-related transactions and possesses wonderful skills in dealing with tricky issues. Zhou is also a great negotiator and is very capable of drafting and negotiating in both English and Chinese, which is critical in cross-border transactions. Zhou has a very strong business sense and can always provide constructive solutions to help us close transactions. We are also impressed by his extremely strong responsiveness to our demands. I would not hesitant to reach out to him at any time, by phone or via email or WeChat.’

Key clients

Bayer

GSK

Amgen

Pfizer

AbbVie Pharmaceutical

Abbott

Mayo Clinic

AstraZeneca

Vivo Ventures

OrbiMed

Sinovac Biotech

SinoPharm Capital

Singlera Genomics

Abbisko

dMed

Hua’s Biomedical

SciClone Pharmaceuticals

3DMedicines, Inc

Innovent Biologics, Inc

Sinocelltech, Inc

Work highlights

  • Advised Abogen Therapeutics on its $720m Series-C and $300m Series-C+ Financing.
  • Acted for Wallaby Medical Holding, Inc on its approximately €500m acquisition of Phenox GmbH and Femtos GmbH.
  • Assisted CVC with its strategic investment in Xi’an Yikang Pharmacy, a leading pharmaceutical retail chain in Northwest China with more than 1,600 pharmacies.

JunHe LLP

The Shanghai-based life sciences and healthcare team at JunHe LLP has a proven track record in handling large cross-border financial transactions such as IPOs and equity investments, M&A and PE and VC financing, which makes it a popular choice for multinational companies, investors, financial instructions, and PE firms. Xudong Tao is especially sough after by biotech and CRO companies to advise on domestic and Hong Kong’s capital markets products. Zoe Wang is recommended for IP matters and handling due diligence in pre-IPO stages. With more than 20 years of experience in representing clients in litigation and arbitration proceeding, Min Zhao is a key contact for disputes and corporate reorganisations. Corporate and M&A specialist Ning Liu, who regularly acts for Fortune 500 companies and major financial institutions, is another name to note.

Practice head(s):

Xudong Tao; Zoe Wang; James Zhu

Other key lawyers:

Ning Liu; Fangzhou Zhang; Yun Shi

Testimonials

‘JunHe’s life sciences team has supported our company with risk control matters and document review related to projects such as clinical trials for many years. It has always been well regarded by our company. In particular, the expertise and professionalism of its lawyers are impressive.’

‘The quality of service provided by Ning Liu’s team in this field has always been good and trustworthy.’

‘The team is highly professional and demonstrates particular strength in assisting clients with negotiations. Serious and dedicated attitude.’

‘Zoe Wang and Fangzhou Zhang are recommended.’

‘Ning Liu’s legal team provides legal services for many leading pharmaceutical and medical enterprises and well-known investment funds in the industry. One of its characteristics is to integrate and provide legal services for the whole industry chain, including daily operations, research and development, clinical trials, drug and medical device registration, FCPA compliance, privacy protection, mergers and acquisitions, minority equity investment and overseas capital markets.’

‘Ning Liu provides customised solutions and not only leads the team himself but also effectively integrates lawyers from other fields within JunHe to serve his clients. He is very sensitive about the client’s business needs and gives timely advice.’ 

‘The JunHe team possesses in-depth knowledge of the life science sector. They are able to provide services in a wide range of areas, including IP prosecution, Licence matters, collaboration agreements, joint ventures, outsourcing, M&A, debt and capital markets, etc.’

‘We particularly appreciate the timely and professional advice of Yun Shi.’

Key clients

BeiGene, Ltd

Goldman Sachs (Asia) L.L.C

Guangzhou Pharmaceutical Holdings Limited

Morgan Stanley Asia Limited

I-MAB Biopharm

PAG Asia Capital (HK) Limited

Vivo Capital

Jiangsu Hengrui Medicines Co., Ltd

Tripod Preclinical Research Laboratories Co., Ltd

Hinova Pharmaceuticals Inc

AffaMed Therapeutics

Goldman Sachs

China International Capital Corporation Limited(CICC)

Sequoia Capital

Highlight Capital

CICC Capital

Bayland Capital

Jiangsu China Life Jiequan Equity Investment Center (Limited Partnership)

J.P. Morgan

Work highlights

  • Advised BeiGene on its A-Share IPO on the SSE STAR Market, assisting it in becoming the first biotechnology company to be listed in Shanghai, Hong Kong and New York.
  • Assisted Asymchem with its listing on the Main Board the Hong Kong Stock Exchange and its A+H share listing.
  • Acted for HUTCHMED (China) on its listing on the Main Board of the Hong Kong Stock Exchange.

Haiwen & Partners

At Haiwen & Partners, the life sciences and healthcare team is particularly known for its strong expertise in transactional matters, often handling large cross-border M&A, IPOs, equity investments, and financings. In addition to its transactional strength, the group is well versed in data protection and privacy, complex collaboration agreements, antitrust, IP licensing and dispute resolution. Splitting her time between Beijing and Shanghai, Tina Wu, who is a key contact for licensing deals and M&A, overseas the practice. Hao Bian, Wenzhen Dai, Rui Feng and Ji Hu are recommended for transactional matters while Frank Wang and Hanguo Zhang focus on IP matters and disputes. In September 2021, the firm welcomed former King & Wood Mallesons' practitioner Yingqi Li boosting the team’s IP and litigation capabilities.

Practice head(s):

Tina Wu

Other key lawyers:

Hao Bian; Wenzhen Dai; Rui Feng; Ji Hu; Yingqi Li; Frank Wang; Hanguo Zhang

Testimonials

‘Haiwen & Partners focuses on cross-border securities, M&A transactions, private equity, and general corporate practice. The team acted as our corporate legal counsel during my company’s successful IPO listing. They behaved professionally and provided valuable advice during the whole IPO application process.’

Key clients

Temasek

JP Morgan Securities (China) Co., Ltd

Shanxi Zhendong Pharmaceutical Co., Ltd

China International Capital Corporation Hong Kong Securities Limited|Morgan Stanley Asia Limited

Clarity Medical Group Holding Limited

Tsing Song Capital

Lilly Asia Ventures

Ali JK Medical Products Limited

Trustar Capital

Work highlights

  • Acted for BeiGene on its listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange, with a total amount of funds raised of approximately ¥22.2bn.
  • Advised Shanxi Zhendong Pharmaceutical Co., Ltd on its sale of 100% of its wholly-owned subsidiary Langdi Zhiyao to FountainVest Partners for ¥5.8bn.
  • Assisted Lepu Biopharma Co., Ltd with its 18A listing on the Main Board of the Hong Kong Stock Exchange.

Shihui Partners

Founded in 2016, Shihui Partners focuses on private equity investment, capital markets and financial transactions, making it a popular choice for investment funds, PE and VC firms and companies seeking advice on transactions in the life sciences and healthcare industry, such as cross-border M&A and funding rounds. Xiangjun Kong, who has extensive experience in handling compliance projects, corporate financing and M&A for pharmaceutical and healthcare companies, overseas the group alongside Jing Lu and Xiaomei Li. Lu is recommended for data protection and licensing matters while Li is a key contact for investment transactions.

Practice head(s):

Xiangjun Kong; Jing Lu; Xiaomei Li

Testimonials

‘The life sciences and healthcare team at Shihui provides our company with year-round legal and project consulting services. With an in-depth knowledge of the industry and business-friendly advice, the team stands out among its competitors.’

‘The solutions proposed are always efficient and clear, providing in-house counsels with easy to implement advice.’ 

‘It is worth mentioning that the lawyer’s fees are very competitive and cost efficient.’

‘Xiangjun Kong not only provides professional and practical solutions , but also provides innovative ideas for addressing risks faced clients.’

‘Xiangjun Kong is very good at breaking down complex legal concepts and explaining them to clients in an easy and concise manner. He is a trusted partner and very professional.’

Key clients

Huaxing Medical Industry Fund

Taiping Industry Investment Manage Co., Ltd

CCB International (Holdings) Co., Ltd

Work highlights

  • Assisted Pfizer Inc in establishing a personal information protection compliance system.
  • Advised Hanhui Pharmaceuticals Co., Ltd on its internal system building, business and compliance legal department compliance training, and business projects.
  • Acted for Juventas Cell Therapy Ltd, a biomedical company focusing on the R&D and the commercialisation of innovative drugs such as immune cell therapy, on various matters, including development and cooperation projects and product registration.

Tian Yuan Law Firm

Tian Yuan Law Firm‘s Beijing-based team is noted for its broad life science and healthcare offering, which includes regulatory compliance, antitrust, IP, dispute resolution and anti-bribery, with a strong focus on M&A, overseas IPOs and investment transactions. The group’s leadership is split between Yixing Li and Juanjuan Song, who is especially sought after by state-owned companies, private equity firms and financial institutions to handle corporate investments and restructurings. Other key names include capital markets and IPO specialist Ping Xu, Xiaohui Zhu who is recommended for venture capital and private equity matters, and M&A expert Yan Liu.

Practice head(s):

Juanjuan Song; Yixing Li

Other key lawyers:

Ping Xu; Xiaohui Zhu; Yan Liu

Work highlights

  • Assisted Gushengtang Holding Limited with its IPO in Hong Kong.
  • Advised Yonghe Medical Group on its listing on the Main Board of the Hong Kong Stock Exchange.
  • Acted for Acotec Scientific Holdings Limited on its successful listing on the Main Board of the Hong Kong Stock Exchange.

Jingtian & Gongcheng

Jingtian & Gongcheng‘s life sciences and healthcare practice is particularly known for its track record in compliance matters, investment deals, IPOs and follow-on offerings as well as M&A. The group is jointly led by Boija Zhao, who advises private equity and venture capital houses on minority investments, and Hanshuo Zhou who is recommended for general corporate matters, licensing issues and product registration. Zhao and Zhou work alongside Yuanpeng Lang and capital markets expert Wei Ren.

Practice head(s):

Hanshuo Zhou; Boija Zhao

Other key lawyers:

Yuanpeng Lang; Wei Ren

Key clients

MicroPort CardioFlow Medtech Corporation Sirnaomics Ltd

Yonghe Medical Group Co., Ltd

Siemens Healthineer

Santen

Conba Group & ZSM Pharma

OrbiMed Advisors LLC

Fosun Pharma

China State-owned Enterprise Mixed Ownership Reform Fund Co., Ltd

Chong Yao Hui Sheng Healthcare Investment Fund (a sub-fund under the C.Q. Pharmaceutical Group)

Qitan Tech

Lightspeed China

LYFE Capital

China Meheco Group Co., Ltd

CPE

CBC Group

IDG Capita

China General Technology (Group) Holding Co Ltd

Universal Medical

China Merchants Capital

Taikang Insurance Group

Xiamen C&D Corporation

State Development & Investment Corp., Ltd. (SDIC)

Sirnaomics Ltd

Yonghe Medical Group Co., Ltd

Shenyang Xingqi Pharmaceutical Co., Ltd

Qiming Venture Partners

Deepwise Limited (DeepWise)

Work highlights

  • Assisted Yonghe Medical Group Co., Ltd with its initial public offering and listing on the Main Board of the Hong Kong Stock Exchange.
  • Acted on the Medlinker Group Companies and the Lifespace Group Companies’ merger.
  • Advised MicroPort CardioFlow Medtech Corporation on its successful listing on the Main Board of the Hong Kong Stock Exchange.

Yuanda China Law Offices

Benefiting from a strategic alliance with Winston & Strawn LLP, Yuanda China Law Offices is well placed to assist domestic and multinational pharmaceutical and life sciences companies with cross-border matters. The practice’s offering covers a wide range of matters, including intellectual property and licensing transactions, M&A, joint ventures and regulatory compliance. The Shanghai-based team is led by James Jiang, who is recommended for government affairs, compliance matters and litigation. Jiang works alongside Jinhua Song, who has extensive experience in advising on PE and VCand M&A transactions.

Practice head(s):

James Jiang

Other key lawyers:

Jinhua Song

Key clients

Shanghai Shyndec Pharmaceutical Co., Ltd

Guangzhou OncoImmune Biotechnology Co., Ltd

Qinhao Pharmaceutical (Suzhou) Co., Ltd

Beijing FORYOR Health Medical Technology

Yinchuan FORYOR Internet Hospital Co., Ltd

Work highlights

  • Acted for Shyndec on its proposed acquisition of a majority stake in a company registered in Beijing.
  • Assisted Beijing FORYOR Health Medical Technology in obtaining an internet hospital licence.
  • Advised Qinhao Pharmaceutical (Suzhou) Co., Ltd on its several rounds of financing.